戻る Agenda
Session 13: EU-RMP Case Study
Session Chair(s)
Carla Barrett, PHARMD
Vice President, Global Risk Management
Novavax, United States
- The EU-RMP group will be asked to provide an overview of the fictional EU-RMP, describe the product’s risks, discuss the additional PV and/or additional RMM activities selected, and present the plan for implementation and evaluation as if they were presenting to an internal Safety Management Team and/or the European Medicines Agency (EMA) for approval.